Eli Lilly and Company (LLY) reported topline results from the LIBRETTO-431 study evaluating Retevmo versus platinum-based chemotherapy plus pemetrexed - with or without pembrolizumab - as an initial treatment for patients with rearranged during transfection fusion-positive advanced or metastatic non-small cell lung cancer. The study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival.
The company will present full results from the LIBRETTO-431 trial at an upcoming medical meeting, submitted to a peer-reviewed journal, and discussed with health authorities.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.